# Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct07151040/  
OnCo record `nct07151040` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TH9619 in colorectal cancer, head and neck squamous cell carcinoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by One-carbon Therapeutics AB, now recruiting.

## Summary

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07151040 by One-carbon Therapeutics AB, with 43 participants planned, started 2025-08-22 and due to reach its primary completion in 2026-12. Interventions recorded: TH9619.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07151040
- Phase: 1/2
- Setting: A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors
- Sponsor: One-carbon Therapeutics AB
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT07151040: https://clinicaltrials.gov/study/NCT07151040

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct07151040.json